CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 119 enrolled
Drug / intervention
TBE booster vaccinationbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02511535
NCT02511535Phase 4Completed
CompareCT.gov

TBE (Tick-borne Encephalitis ) Vaccination in Allergic Patients

Medical University of Vienna·interventional·Posted Jul 30, 2015·Updated Oct 25, 2019

In Brief

A Phase 4 clinical trial evaluating TBE booster vaccination for Vaccine Responsiveness in Allergy and Vaccine Responsiveness During Allergy De-sensitization Treatment. Completed, enrolled 119 participants across 1 site.

Detailed Summary

Allergic patients especially those undergoing de-sensitization treatment have an altered immune responsiveness. The investigators aim to find out whether this influences immune responses to primary and booster vaccinations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccine Responsiveness in Allergy, Vaccine Responsiveness During Allergy De-sensitization Treatment
CountriesAustria
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 30, 2015
Enrollment StartSep 1, 2013
Primary CompletionFeb 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 10.9 years ago

Interventions

TBE booster vaccinationbiological